Inhibition of the insulin-like growth factor-1 receptor enhances effects of simvastatin on prostate cancer cells in Co-culture with bone

Cancer Microenvironment

Volumn 6, Issue 3, 2013, Pages 231-240

  Nordstrand, Annika ^a   Lundholm, Marie ^a   Larsson, Andreas ^a   Lerner, Ulf H ^a,b   Widmark, Anders ^a   Wikström, Pernilla ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Bone metastases; Cholesterol; IGF 1R; Prostate cancer; Simvastatin

Indexed keywords

ANDROGEN RECEPTOR; NVP AEW 541; SIMVASTATIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE; CALVARIA; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; TUMOR MICROENVIRONMENT;

EID: 84891002824     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-013-0129-z     Document Type: Article

References (44)

1. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27(3):165-176. doi: 10.1053/ctrv.2000.0210
2. Linkhart TA, Mohan S, Baylink DJ (1996) Growth factors for bone growth and repair: IGF, TGF beta and BMP. Bone 19(1 Suppl):1S-12S
3. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD (2000) Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82(4):858-864. doi: 10.1054/bjoc.1999.1012
4. Nordstrand A, Nilsson J, Tieva A, Wikstrom P, Lerner UH, Widmark A (2009) Establishment and validation of an in vitro co-culture model to study the interactions between bone and prostate cancer cells. Clin Exp Metastasis 26(8):945-953. doi: 10.1007/s10585-009-9285-4
5. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schroder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP Jr, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149(7):461-471
6. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124(10):2416-2429. doi: 10.1002/ijc.24202
7. Hewish M, Chau I, Cunningham D (2009) Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov 4(1):54-72
8. Turney BW, Turner GD, Brewster SF, Macaulay VM (2011) Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression. BJU Int 107(9):1488-1499. doi: 10.1111/j.1464-410X.2010. 09556.x
9. de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connely M, Terstappen LW, Gualberto A (2007) Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 13(12):3611-3616. doi: 10.1158/1078-0432.CCR-07-0268
10. Ryan CJ, Haqq CM, Simko J, Nonaka DF, Chan JM, Weinberg V, Small EJ, Goldfine ID (2007) Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol 25(2):134-140. doi: 10.1016/j.urolonc.2006.07.019
11. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM (2002) Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62(10):2942-2950
12. Parrizas M, Saltiel AR, LeRoith D (1997) Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J Biol Chem 272(1):154-161
13. Kulik G, Weber MJ (1998) Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol 18(11):6711-6718
14. Grothey A, Voigt W, Schober C, Muller T, Dempke W, Schmoll HJ (1999) The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J Cancer Res Clin Oncol 125(3-4):166-173
15. Buck E, Mulvihill M (2011) Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opin Investig Drugs 20(5):605-621. doi: 10.1517/13543784.2011.558501
16. Heidegger I, Pircher A, Klocker H, Massoner P (2011) Targeting the insulin-like growth factor network in cancer therapy. Cancer Biol Ther 11(8):701-707
17. Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikstrom P (2010) Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One 5(12):e14175. doi: 10.1371/journal.pone.0014175
18. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR (2005) Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 115(4):959-968. doi: 10.1172/JCI19935
19. Hoque A, Chen H, Xu XC (2008) Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomark Prev 17(1):88-94. doi: 10.1158/1055-9965.EPI-07-0531
20. Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T (2011) Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer 47(6):819-830. doi: 10.1016/j.ejca.2011.01.005
21. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R, Evans DB, Fabbro D, Furet P, Porta DG, Liebetanz J, Martiny-Baron G, Ruetz S, Hofmann F (2004) In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5(3):231-239
22. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, Garcia-Echeverria C, Hofmann F, Picci P (2005) Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65(9):3868-3876. doi: 10.1158/0008-5472.CAN-04-3192
23. Carlberg M, Dricu A, Blegen H, Wang M, Hjertman M, Zickert P, Hoog A, Larsson O (1996) Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth. J Biol Chem 271(29):17453-17462
24. Sekine Y, Furuya Y, Nishii M, Koike H, Matsui H, Suzuki K (2008) Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Biochem Biophys Res Commun 372(2):356-361. doi: 10.1016/j.bbrc.2008.05.043
25. Yokomizo A, Shiota M, Kashiwagi E, Kuroiwa K, Tatsugami K, Inokuchi J, Takeuchi A, Naito S (2011) Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells. Prostate 71(3):298-304. doi: 10.1002/pros.21243
26. Dehm SM, Tindall DJ (2011) Alternatively spliced androgen receptor variants. Endocr Relat Cancer 18(5):R183-R196. doi: 10.1530/ERC-11-0141
27. Ohlson N, Wikstrom P, Stattin P, Bergh A (2005) Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate 62(4):307-315. doi: 10.1002/pros.20139
28. Ohlson N, Bergh A, Persson ML, Wikstrom P (2006) Castration rapidly decreases local insulin-like growth factor-1 levels and inhibits its effects in the ventral prostate in mice. Prostate 66(16):1687-1697. doi: 10.1002/pros.20368
29. Cohen P, Peehl DM, Lamson G, Rosenfeld RG (1991) Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73(2):401-407
30. Nickerson T, Pollak M, Huynh H (1998) Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4 and 5. Endocrinology 139(2):807-810
31. Ohlson N, Bergh A, Stattin P, Wikstrom P (2007) Castration-induced epithelial cell death in human prostate tissue is related to locally reduced IGF-1 levels. Prostate 67(1):32-40. doi: 10.1002/pros.20480
32. Plymate SR, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, Montgomery RB, Ludwig DL, Wu JD (2007) An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res 13(21):6429-6439. doi: 10.1158/1078-0432.CCR-07-0648
33. Allen GW, Saba C, Armstrong EA, Huang SM, Benavente S, Ludwig DL, Hicklin DJ, Harari PM (2007) Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 67(3):1155-1162. doi: 10.1158/0008-5472.CAN- 06-2000
34. Descamps G, Gomez-Bougie P, Venot C, Moreau P, Bataille R, Amiot M (2009) A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45. Br J Cancer 100(2):366-369. doi: 10.1038/sj.bjc.6604839
35. Baumann P, Hagemeier H, Mandl-Weber S, Franke D, Schmidmaier R (2009) Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001. Anticancer Drugs 20(4):259-266. doi: 10.1097/CAD.0b013e328328d18b
36. Wu JD, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, Montgomery RB, Ludwig DL, Plymate SR (2006) Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin Cancer Res 12(20 Pt 1):6153-6160. doi: 10.1158/1078-0432. CCR-06-0443
37. Lingwood D, Simons K (2010) Lipid rafts as a membrane-organizing principle. Science 327(5961):46-50. doi: 10.1126/science.1174621
38. Li YC, Park MJ, Ye SK, Kim CW, Kim YN (2006) Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol 168(4):1107-1118, quiz 1404-1105
39. Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24(50):7455-7464. doi: 10.1038/sj.onc.1209085
40. Hong S, Huo H, Xu J, Liao K (2004) Insulin-like growth factor-1 receptor signaling in 3T3-L1 adipocyte differentiation requires lipid rafts but not caveolae. Cell Death Differ 11(7):714-723. doi: 10.1038/sj.cdd.4401405
41. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69(1):16-22. doi: 10.1158/0008-5472.CAN-08-2764
42. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69(6):2305-2313. doi: 10.1158/0008-5472.CAN-08-3795
43. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A, Wikstrom P (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6(4):e19059. doi: 10.1371/journal.pone.0019059
44. Lerner UH (1987) Modifications of the mouse calvarial technique improve the responsiveness to stimulators of bone resorption. J Bone Miner Res 2(5):375-383. doi: 10.1002/jbmr.5650020504